News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actelion Ltd. (ALIOF.PK) Announces U.S. Commercial Availability of OPSUMIT® (macitentan) as of November 4


11/4/2013 10:17:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Actelion (SIX: ATLN) today announced the commercial availability of OPSUMIT® (macitentan) 10mg, an oral, dual endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. PAH is a chronic, life-threatening disorder that can severely compromise the function of the lungs and heart. The U.S. Food and Drug Administration (FDA) approved OPSUMIT on October 18, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES